Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Singh, D.D. | - |
dc.contributor.author | Parveen, A. | - |
dc.contributor.author | Yadav, D.K. | - |
dc.date.accessioned | 2021-12-16T01:40:51Z | - |
dc.date.available | 2021-12-16T01:40:51Z | - |
dc.date.created | 2021-11-11 | - |
dc.date.issued | 2021-11 | - |
dc.identifier.issn | 2227-9059 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/82948 | - |
dc.description.abstract | Triple-negative breast cancer is a combative cancer type with a highly inflated histological grade that leads to poor theragnostic value. Gene, protein, and receptor-specific targets have shown effective clinical outcomes in patients with TNBC. Cells are frequently exposed to DNA-damaging agents. DNA damage is repaired by multiple pathways; accumulations of mutations occur due to damage to one or more pathways and lead to alterations in normal cellular mechanisms, which lead to development of tumors. Advances in target-specific cancer therapies have shown significant momentum; most treatment options cause off-target toxicity and side effects on healthy tissues. PARP (poly(ADP-ribose) polymerase) is a major protein and is involved in DNA repair pathways, base excision repair (BER) mechanisms, homologous recombination (HR), and nonhomologous end-joining (NEJ) deficiency-based repair mechanisms. DNA damage repair deficits cause an increased risk of tumor formation. Inhibitors of PARP favorably kill cancer cells in BRCA-mutations. For a few years, PARPi has shown promising activity as a chemotherapeutic agent in BRCA1-or BRCA2-associated breast cancers, and in combination with chemotherapy in triple-negative breast cancer. This review covers the current results of clinical trials testing and future directions for the field of PARP inhibitor development. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | Biomedicines | - |
dc.title | Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000727889800001 | - |
dc.identifier.doi | 10.3390/biomedicines9111512 | - |
dc.identifier.bibliographicCitation | Biomedicines, v.9, no.11 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85118347728 | - |
dc.citation.title | Biomedicines | - |
dc.citation.volume | 9 | - |
dc.citation.number | 11 | - |
dc.contributor.affiliatedAuthor | Parveen, A. | - |
dc.contributor.affiliatedAuthor | Yadav, D.K. | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | Breast cancer | - |
dc.subject.keywordAuthor | DNA damage repair | - |
dc.subject.keywordAuthor | PARP (poly(ADP-ribose) polymerase) | - |
dc.subject.keywordAuthor | Signaling pathway | - |
dc.subject.keywordAuthor | Therapeutic target | - |
dc.subject.keywordAuthor | TNBC | - |
dc.subject.keywordPlus | GERMLINE BRCA MUTATION | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | POLY(ADP-RIBOSE) POLYMERASE | - |
dc.subject.keywordPlus | NEOADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | SYNTHETIC LETHALITY | - |
dc.subject.keywordPlus | DOSE-ESCALATION | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | GENOME-WIDE | - |
dc.subject.keywordPlus | DNA BREAKS | - |
dc.subject.keywordPlus | OLAPARIB | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.